Approaches to improve soil fertility in sub-Saharan Africa.

Soil fertility provides the foundation for nutritious food production and resilient and sustainable livelihoods. A comprehensive survey and summit meeting were conducted with the aims of understanding barriers to enhancing soil fertility in sub-Saharan Africa and providing evidence-based recommendations. The focus regions were West Africa, East Africa, the Great Lakes region, and Ethiopia. Overall recommendations were developed with four emerging themes: (1) strengthening inorganic fertilizer-based systems, (2) access to and use of quality organic inputs, (3) capacity building along the entire knowledge-transfer value chain, and (4) strengthening farming systems research and development across biophysical and socio-economic factors. The evidence-based process and methodology for prioritizing these recommendations makes these findings useful for setting out action plans for future investments and strategies. Access to inorganic fertilizer, its use, and related implementation issues were prominent considerations; nevertheless, biophysical and socio-economic barriers and solutions were identified as equally important to building soil fertility and natural resources. Soil management initiatives should focus on providing holistic solutions covering both biophysical and socio-economic aspects along the entire value chain of actors and creating an enabling environment for adoption. A broader view of soil fertility improvement using all available options including both inorganic and organic sources of nutrients and farming system approaches are highly recommended.

CJ-13610, an orally active inhibitor of 5-lipoxygenase is efficacious in preclinical models of pain.

Zileuton, a redox and iron chelator 5-lipoxygenase (5-LOX) inhibitor and, leukotriene receptor antagonists are presently used clinically in the long term treatment of asthma. Recent data implicate 5-LOX pathway in pain signaling. We report 5-LOX expression in the central nervous system (CNS) and analyze the pain efficacy of a new class of non redox, non iron chelating 5-LOX inhibitor. CJ-13610, 4-(3-(4-(2-methyl-1H-imidazol-1-yl) phenylthio) phenyl)-tetrahydro-2H-pyran-4-carboxamide, demonstrated antihyperalgesic activity in inflammatory pain models including the acute carrageenan model and the chronic inflammatory model using complete Freund's adjuvant. Following complete Freund's adjuvant stimulus leukotrieneB(4) concentration in the brain was elevated (9+/-1 ng/g, mean+/-S.E.M.) by about 3 times that of the control group (3+/-0.11, mean+/-S.E.M.). Hyperalgesia and leukotrieneB(4) concentration were both reversed following CJ-13610 treatment. Furthermore, we demonstrate CJ-13610 efficacy against osteoarthritis like pain using the rat medial meniscal transection model. CJ-13610 at oral doses of 0.6, 2 and 6 mg/kg/day reversed two modalities of pain in this model; tactile allodynia and weight bearing differential. Taken together, these data suggest that 5-LOX pathway and the leukotriene products are important mediators of pain.